HOME >> MEDICINE >> NEWS
Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions

SAN DIEGO - The results of a Phase I/II study of NUVANCE™ (IL-4 receptor) in adult patients with moderate asthma will be featured at the Late-Breaker Abstract Session at the American Academy of Allergy, Asthma and Immunology's (AAAAI) 56th Annual Meeting (March 3-8 in San Diego, California).

WHEN: Saturday, March 4, 2000, 3:00 pm

WHERE: Late Breaker: New Therapies Mini-symposium, Room 8, Upper Level of the San Diego Convention Center.

WHO: Dr. Jonathan Corren, MD, Medical Director, Allergy Research Foundation, and lead investigator will present the results of Phase I/II study of NUVANCE™ in adult patients with moderate asthma. Dr. Corren is affiliated with the University of California, Los Angeles.

A presentation entitled, "Cytokines and Cytokine Therapy for Allergic Diseases: Which One is the Most Critical? Il-4 and IL-4 Receptor Antagonists in Allergic Disease," will also be featured at the AAAAI Annual Meeting.

WHEN: Monday, March 6, 2000, 8:45 am - 10:45 am

WHERE: Asthma Therapy Symposium, Marina Ballroom G, Level 3, South Tower, Marriott.

WHO: Dr. Jan Agosti, Medical Director, Immunex Corp., will present scientific evidence and clinical data demonstrating the potential of IL-4 inhibition to improve lung function and control the symptoms of people with asthma.

Interleukin-4 (IL-4) is a naturally occurring cytokine, or immune system protein, that has been commonly associated with the development of asthma and allergies. It binds to specific IL-4 receptors (IL-4R) on the surface of cells in the body or to naturally occurring soluble receptors that circulate throughout the body. Increased levels of IL-4 appear to be related to increased severity of asthma that results in difficulty in breathing. Immunex scientists used recombinant DNA technology to produce a soluble IL-4 receptor, a molecule the company names NUVANCE. When IL-4 binds with NUVANCE instead of cell-surface IL-4R, the effects of IL-4 may be block
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
1-Mar-2000


Page: 1 2

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
8. Results of NUVANCE phase I/II asthma trial presented
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. UI Study Yields Encouraging Results For New Breast Cancer Treatment
11. Ph.D. Degree Research Results In Patent For Low-Cost Pharmaceutical Filters Made From Seafood Waste

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2018)... FRANCISCO (PRWEB) , ... November 15, 2018 , ... Through ... microbiome research support in study design, planning, sample collection, and analysis to a team ... a randomized controlled trial to test the effects on the microbiome of a low-fat ...
(Date:11/15/2018)... ... November 15, 2018 , ... The National Cancer Institute estimates that ... is the primary risk factor for cancer and we typically associate the disease with ... of 45. And with aggressive treatment and advanced therapies, increasing numbers of these patients ...
(Date:11/15/2018)... , ... November 15, 2018 , ... West Virginia and ... and 45th in the country when it comes to the number of weight-loss surgeries ... analysis of factors that may determine utilization of bariatric surgery in the 50 states ...
(Date:11/15/2018)... ... November 15, 2018 , ... Access today ... paperless, web-based eForms solution for hospitals . This release features tight integration with ... directly from any of these systems, have patients electronically sign them on tablets, ...
(Date:11/15/2018)... ... November 15, 2018 , ... GoInvo, a ... “Loneliness in Our Human Code”, ( https://www.goinvo.com/vision/loneliness-in-our-human-code/ ) the latest in a series ... visual essay explores how social determinants of health, with a focus on loneliness, ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... ... November 15, 2018 , ... Triple W, an innovator of ... version of the companion app for DFree®, the first wearable device for incontinence that ... , seniors, children and disabled people with bladder control issues have a convenient and ...
(Date:11/15/2018)... LOS ANGELES (PRWEB) , ... November 15, 2018 ... ... the potential of cosmetic and reconstructive surgery in their lives will soon be ... MD. , After months of work, Alton Ingram, MD, created the now-popular blog ...
(Date:11/15/2018)... ... November 15, 2018 , ... ... today announced a strategic partnership with Formativ Health, a technology-enabled, health-services company, ... perform platform integrations that connect Formativ Health’s clients’ Healthcare IT to the ...
Breaking Medicine Technology:
Cached News: